66 results about "Helicobacter Infections" patented technology

The present invention concerns polymer particle vaccine delivery systems in which a water insoluble protein antigen, e.g. a lipidated HpaA protein, is incorporated with particles comprising a polymer matrix. The present invention also concerns a method for incorporating such a water insoluble protein antigen with a polymer matrix in order to produce a polymer particle vaccine delivery system. In addition, the invention also provides a vaccine composition comprising the polymer particle delivery system. The vaccine can be used to treat and/or reduce the risk of for example Helicobacter infection.

The invention discloses a recombinant helicobacter pylori protein vaccine and a preparation method thereof. The active ingredient recombinant fusion protein of the vaccine consists of recombinant LTAl-Ureal protein and LTB protein, the amino acid sequence of the recombinant LTAl-Ureal protein is shown as Seq ID No.1, the amino acid sequence of the LTB protein is shown as Seq ID No.2. Epitope-containing gene segments of Hp urease A subunit is inserted in an LTA subunit-encoded gene, a toxic part-containing segment is replaced to prepare a recombinant plasmid so as to express and obtain recombinant fusion protein polymer as a vaccine antigen, the fusion antigen and LTB protein pentamer are combined to form a hexamer structure, so that not only can the structure basis and activity of an LT mucosa adjuvant be remained, but also the toxicity can be removed, the immune response of organism muscosa can be effectively induced through immunity of mucosa path, to generate specific IgA antibody. The recombinant helicobacter pylori protein vaccine provides a vaccine manner for preventing and treating infection of helicobacter pylori.

This invention relates to novel compounds having the structural diagram (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of H. pylori infection.

This invention relates to novel compounds having the Formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of H. pylori infection.

The invention discloses lactobacillus rhamnosus and application thereof in inhibition of helicobacter pylori, and belongs to the technical fields of microorganisms and medicines. The invention provides a lactobacillus rhamnosus strain CCFM1119, and the lactobacillus rhamnosus strain CCFM1119 has the effect of preventing and/or treating helicobacter pylori infection. (1) the lactobacillus rhamnosusstrain CCFM1119 can obviously relieve gastrointestinal symptoms of a patient infected by helicobacter pylori; (2) the lactobacillus rhamnosus strain CCFM1119 can significantly reduce the colonizationamount of helicobacter pylori in the body of a patient infected by helicobacter pylori; and (3) the lactobacillus rhamnosus strain CCFM1119 can significantly improve the removal rate of helicobacterpylori in the body of a patient infected by helicobacter pylori, and thus the lactobacillus rhamnosus strain CCFM1119 has a huge application prospect in the preparation of products (such as foods or medicines) for preventing and/or treating helicobacter pylori infection.

The present invention discloses recombinant vaccine based on the Helicobacter pylori neutral granulocyte activated protein A (NapA) antigen and its preparation process and application in inducing the protecting immune reaction resisting Helicobacter pylori infection. The vaccine consists of independent Helicobacter pylori NapA as the basic active component, or the fusion protein comprising Helicobacter pylori NapA, adhesion HpaA and urase B subunit active segment (UreB414), and one or several kinds of pharmaceutically acceptable adjuvant and excipient.

Methods of diagnosing Helicobacter pylori infection or associated conditions are based in part on the correlation of the presence of a α-L-fucosidase 2 marker with the infection. Methods and compositions for treating or preventing Helicobacter pylori infection or associated conditions are based in part on administering an α-L-fucosidase 2 inhibitor to an infected subject or a subject at risk of developing the infection.

The invention discloses a traditional Chinese medicine for treating chronic gastritis caused by deficiency cold in spleen and stomach and a preparation method of the traditional Chinese medicine. The traditional Chinese medicine comprises the following raw materials: orange peel, agilawood, silverweed cinquefoil root, stichopus japonicas, buckeye, hispid arthraxon, viburnum fordiae, baked ginger, pericarpium arecae, thlaspi arvense, fingered citron, sambucus chinensis, persimmon calyx, white egret flower, starfish, angelica sinensis, rhizoma cyperi, alkaline marin, cynanchum wilfordii, procumbent speedwell, pericarpium citri reticulatae, herba cistanche, fructus psoraleae, castanea seguinii, trifoliate orange, fructus amomi, saccatespur larkspur, sandalwood, prostrate hemlock, fructus piperis longi, zanthoxylum avicennae, poria cocos, lucid ganoderma, radix pseudostellariae, rhizoma atractylodis macrocephalae, primula obconica and cyananthus argernteus marg. The traditional Chinese medicine for treating chronic gastritis caused by deficiency cold in spleen and stomach has the functions of warming middle, invigorating spleen and regulating stomach to relieve pain, is mainly used for treating chronic gastritis caused by deficiency cold in spleen and stomach, is capable of treating treatment based on syndrome differentiation by using the theory of traditional Chinese medicine, is relatively high in pertinence, can be used for treating the same disease with different methods according to the different clinical stages of the diseases and treating different diseases with the same method according to the similar diseases, has the effects of removing helicobacter infections, protecting gastric mucosa, eliminating cold to stop pain and improving overall immunity of the organism, and has the advantages of being quick in effect, high in effective rate, obvious in curative effect, short in treatment course, free of toxic and side effects and low cost.

The invention relates to rabeprazole sodium for injection as well as a preparation method and a detection method thereof. The rabeprazole sodium for injection is a medical preparation for injection, which is prepared from rabeprazole sodium as an active ingredient, a stabilizing agent, a pH value regulator and pharmaceutically acceptable auxiliary materials. The rabeprazole sodium for injection, disclosed by the invention, is rapid in effect taking and high in bioavailability, is used for treating gastrohelcosis, duodenal ulcer, erosive gastroesophageal reflux disease, helicobacter pylori injection, Zollinger-Ellision syndrome and the like and is more suitable for being used as a substitutive medicament when oral preparations for treating the diseases have no effect.

The invention discloses an intramolecular adjuvant-containing recombinant gene for preventing and treating helicobacter pylori, protein and a biological product. the multi-target recombinant gene comprises a multi-target fusion polypeptide having an amino acid sequence shown in a SEQ ID NO:2, a multi-target recombinant gene for coding the multi-target fusion polypeptide having the nucleotide sequence shown in a SEQ ID NO:2, and invention also has an application of a specific antibody of the above multi-target recombinant gene or the above multi-target fusion polypeptide or the multi-target fusion polypeptide as the biological product for preventing and treating helicobacter pylori infection. According to the invention, an intramolecular adjuvant CTB for removing signal peptide is added at N segment of a recombinant helicobacter pylori multi-target fusion polypeptide (rIB), so that prevention and treatment effect for the helicobacter pylori infection can be increased.

The invention discloses a chemical medicine composition for treating helicobacter pylori (Hp) infection of adults through oral administration. The composition at least comprises fosfomycin or pharmaceutical salts such as a sodium salt, a calcium salt, fosfomycin trometamol and aminoglycoside medicines of the fosfomycin of a common dosage of an adult, and the aminoglycoside medicines are selected from tobramycin, netilmicin, etimicin, isepamicin, amikacin and common salts such as sulfate, of the medicines.

The invention discloses a composition for resisting helicobacter pylori and the application of the composition. The composition comprises linolenic acid capsules, a zinc preparation (zinc gluconate orpolaprezinc) and a proton pump inhibitor. The pharmaceutical composition can inhibit helicobacter pylori in vivo and in vitro by combined use, has a good effect on treatment of gastritis and other related diseases caused by helicobacter pylori infection, and especially has a good effect on refractory gastritis caused by drug-resistant helicobacter pylori infection. According to the composition, helicobacter pylori infection can be cured under the condition that antibiotics are not used, the cure rate is increased, and the occurrence rate of antibiotic resistance is reduced.

The present invention relates to the new use of acidophilic lactobacillus in preparing functional food and medicine, and is especially health article and medicine for preventing and treating chronic gastropathy prepared with acidophilic lactobacillus. Acidophilic lactobacillus with specific pyloric helicobacter antagonizing effect is cultured, separated and screened from human gastrointestinal tract excrement, and inoculated to food or medicine acceptable carrier. The acidophilic lactobacillus has the specific pyloric helicobacter antagonizing characteristics of bacteriostasis ring diameter detected via agar perforating process greater than 2 cm, pyloric helicobacter urease inhibiting activity in 2 hr greater than 50 % and 4 hr inhibition of pyloric helicobacter growth greater than 1 LgCFU/ml. Taking the health article or medicine of the present invention can preventing and treating chronic gastropathy caused by pyloric helicobacter infection.

The present invention relates to immunogenic compositions and their use in the prevention or treatment of diseases or disorders caused by or associated with Helicobacter pylori, in particular H. pylori infection and gastroduodenal disorders caused by H. pylori. The present invention further relates to methods of detecting H. pylori infection in a subject.

The invention discloses a recombinant helicobacter pylori multi-epitope tandem vaccine and a preparation method thereof. The vaccine is composed of an escherichia coli labile toxin B subunit (LTB) andepitopes selected from helicobacter pylori antigens HpaA, UreB and CAT. The helicobacter pylori multi-tandem epitope vaccine can generate a high-titer antibody sIgA and a specific IgG antibody in serum in gastric mucosa, and the specific antibody IgG can significantly inhibit helicobacter pylori urease activity. The vaccine can be used for preventing or treating helicobacter pylori infection.

The invention discloses lactobacillus reuteri capable of resisting helicobacter pylori infection and application of the lactobacillus reuteri. The lactobacillus reuteri is identified as lactobacillus reuteri, the strain name is DRTR, the lactobacillus reuteri is preserved in the China Center for Type Culture Collection, the preservation date is October 19, 2020, and the preservation number is CCTCC NO: M2020597. The lactobacillus reuteri provided by the invention has good gastric acid resistance, can inhibit proliferation of helicobacter pylori and urease activity, and reduces adhesion of the helicobacter pylori to human gastric mucosa cells GES-1; the helicobacter pylori is prepared into a corresponding product for inhibiting helicobacter pylori infection, so that the growth of helicobacter pylori in a stomach environment can be inhibited; when the compound is combined with antibiotics to treat helicobacter pylori infection, the eradication rate can be remarkably increased, side effects in the treatment process are reduced, and the compound has very high application value.

The invention belongs to the field of medical data mining, and particularly relates to a helicobacter pylori stomach video full-automatic intelligent analysis system and a marking method thereof.The helicobacter pylori stomach video full-automatic intelligent analysis system comprises an image acquisition module, an image preprocessing module, an effective frame module, an anatomical position positioning module, a deep learning module and a mark display module; the image preprocessing module is used for preprocessing images of a video stream, the effective frame module is used for classifying and screening the images of the video stream, and the anatomical position positioning module is used for identifying the specific position of an endoscope in the stomach currently. And the deep learning module is used for predicting the helicobacter pylori infection probability for the pictures of different anatomical positions. In the testing process, a doctor does not need to step on a pedal to input a specific picture for helicobacter pylori infection recognition, manual intervention is not needed in the whole process, and full automation and high intelligence can be achieved.

The invention discloses a probiotic agent PAPCH for preventing and treating helicobacter pylori infection and a preparation method of the probiotic agent PAPCH. The probiotic agent PAPCH comprises lactobacillus casei lyT-7 and a protective agent, The preservation number of the lactobacillus casei lyT-7 is CCTCC NO: M 2010197, the preservation time is August 9th, 2010, and the preservation addressis China Center for Type Culture Collection (CCTCC). The addition quantity of the protective agent is 50-150wt% of the use quantity of the lactobacillus casei lyT-7. The prepared probiotic agent can effectively inhibit adhesion of the helicobacter pylori on gastric epithelial cells, inflammatory reaction and immune response caused by the helicobacter pylori, and oxidation reaction induced by helicobacter pylori infection, can directly inhibit and even kill the helicobacter pylori, besides, can improve the micro-ecological environment of gastrointestinal tracts, and can reduce adverse effects of antibiotics.

The invention discloses lactobacillus sake capable of being co-aggregated with helicobacter pylori and application of the lactobacillus sake, and belongs to the technical field of microorganisms and the technical field of medicines. The invention provides a lactobacillus sake 1199 strain, which is preserved in the Guangdong Province Microbial Culture Collection Center, the preservation number is GDMCC No: 61953, and the preservation date is September 26, 2021. The lactobacillus sake 1199 strain has the advantages that the lactobacillus sake 1199 strain is preserved in the Guangdong Province Microbial Culture Collection Center, the preservation number is GDMCC No: 61953; the lactobacillus sake CCFM1199 bacterial suspension and helicobacter pylori can generate a co-aggregation effect in artificial gastric juice (pH = 4), and the adhesive force of the helicobacter pylori to AGS cells can be remarkably reduced; the lactobacillus sake CCFM1199 has a huge application prospect in the preparation of products (such as food or medicines and the like) for preventing and/or treating helicobacter pylori infection.

The invention provides an expiration detection method and device for helicobacter pylori infection and related inflammation. The method and device are characterized in that: general beverages and foodare forbidden for 3 hours before testing, and barbecue food is forbidden for 8-12 hours; the expiration NO concentrations before and after administration of a substrate capable of promoting NO generation and stabilization are detected; and helicobacter pylori infection and related inflammation are detected according to the difference change of expiration NO before and after administration of thesubstrate. The substrate for realizing the method consists of urea, acid and salt in a certain proportion. The expiration NO detection device is composed of an expiration sampling module and an expiration analysis module and comprises an expiration flow sensor, a pressure sensor, a temperature and humidity sensor, a CO2 sensor and an NO sensor.

The invention discloses a newly screened streptococcus thermophilus strain and application of the newly screened streptococcus thermophilus strain to prevention or treatment of helicobacter pylori infection, and belongs to the technical field of applied microbiology. The streptococcus thermophilus strain is preserved in the China General Microbiological Culture Collection Center on July 6, 2020, and has the preservation number being CGMCC No. 20189. The streptococcus thermophilus strain is subjected to mixed culture with lactobacillus acidophilus, and an H.pylori in-vitro antibacterial experiment is carried out through an oxford cup method, the antibacterial effect is judged to be highly sensitive, an obvious antibacterial effect acts on H.pylori, and the strain and studying basis is provided for development of yoghourt and health care products for inhibiting helicobacter pylori.